Review
First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting
-
* Corresponding author: Lillian L Siu Lillian.Siu@uhn.on.ca
Division of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Canada
Journal of Hematology & Oncology 2008, 1:20 doi:10.1186/1756-8722-1-20
Published: 29 October 2008Abstract
This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, GRN163L, LY2181308, PF-00562271, RAV12, RTA 402, XL765, and the survivin vaccine.